unsubordinated obligations of AbbVie and will rank equally in right of payment with all of AbbVie’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. AbbVie may redeem the fixed-rate senior notes prior to maturity at a redemption price equal to the greater of the principal amount or the sum of present values of the remaining scheduled payments of principal and interest plus a make-whole premium. AbbVie may also redeem the fixed-rate senior notes at par between one and six months prior to maturity.
In March 2025, the company repaid $
3.0
billion aggregate principal of
3.80
% senior notes at maturity.
Short-Term Borrowings
Short-term borrowings included commercial paper borrowings of $
1.6
billion as of March 31, 2025 and there were
no
amounts outstanding as of December 31, 2024. The weighted-average interest rate on commercial paper borrowings was
4.59
% for the three months ended March 31, 2025 and
5.54
% for the three months ended March 31, 2024.
Subsequent to March 31, 2025, the company entered into a $
4.0
billion 364-day term loan credit agreement.
No
amounts were borrowed under the term loan credit agreement as of the date of filing of this Quarterly Report on Form 10-Q.
In January 2025, AbbVie entered into a new $
3.0
billion
five-year
revolving credit facility that matures in January 2030 which is in addition to the existing $
5.0
billion
five-year
revolving credit facility that matures in March 2028. The revolving credit facilities are available to support AbbVie’s commercial paper program and enable the company to borrow funds to meet liquidity requirements on an unsecured basis at variable interest rates and contain various covenants. At March 31, 2025, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant.
No
amounts were outstanding under the company's credit facilities as of March 31, 2025 and December 31, 2024.
Financing Related to ImmunoGen and Cerevel Therapeutics Acquisitions
In connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, in February 2024, the company issued $
15.0
billion aggregate principal amount of unsecured senior notes. The notes are unsecured, unsubordinated obligations of AbbVie and will rank equally in right of payment with all of AbbVie’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. AbbVie may redeem the fixed-rate senior notes prior to maturity at a redemption price equal to the greater of the principal amount or the sum of present values of the remaining scheduled payments of principal and interest on the fixed-rate senior notes to be redeemed plus a make-whole premium. AbbVie may also redeem the fixed-rate senior notes at par between one and six months prior to maturity. In connection with the offering, debt issuance costs incurred totaled $
99
million and debt discounts totaled $
37
million, which are being amortized over the